Feedback on the Tenth International Conference on AIDS/International Conference on STD (7–11 August 1994)

The AIDS Strategy in Yokohama City. Yokohama City Public Health Bureau, 1994.

Merson MH. Global status of the HIV/AIDS epidemic and the response. PS1, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Ngeow YF. STD and HIV epidemiology in Asia. PS7, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Bertozzi SM. The impact of HIV/AIDS. PS30, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Chin J. Estimation and projection of HIV/AIDS in Asia. 181C, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Lange J. When to start Antiretroviral treatment. RT 25, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Volberding P. Zidovudine in early symptomatic HIV disease: a controlled trial in subjects with greater than 500 CD4+ cells/μl. 355B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Ruedy N. Results of long term follow-up of a double blind study of ddI us continued AZT among individuals with CD4's 200–500/mm3. 358B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Mayers DL. Virologic response to ddI following prolonged AZT treatment. 359B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Graham N. Survival Advantage of combination therapy versus sequential therapy in MACs. Wellcome Satellite Symposium.

Thompson M. Impact of AZT monotherapy versus sequential or combination antiretroviral therapy on survival. PB279, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Collier A. Comparative study of R031–8959 and zidovudine (ZDV) vs. ZDV and zalcitabine (ddC) vs. Ro 31 8959, ZDV and ddC. 58B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Stein DS. Acyclovir/zidovudine combination therapy and AIDS survival. 60B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Kinloch S. Treatment of primary HIV infection with zidovudine. 2B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Vella S. Update on antiretroviral therapy. PS 3, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

Blanche S. Materno-fetal transmission. PS11, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Balsey JF. Mother to child infection. SR-2, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Bryson Y. Protective role of zidovudine in reduction of maternal-fetal HIV transmission during pregnancy. Wellcome Satellite Symposium. Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Kumar MR Hughes PF Khurranna A. Zidovudine use in 104 pregnancies: birth defects. 357B, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43:1–20.

Buchbinder S Elbeik T Harrer Healthy long-term HIV positives: viral burden and cell-mediated immunity. 007C, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Ho DD. Long term non-progressor. PS10, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Easterbrook PJ Forster S Henderson D Immunological characteristics of HIV—infected non-progressors. 008C, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Fauci AS. Host factors in the immunopathogenesis of HIV disease. PS2, Tenth International Conference on AIDS/International Conference on STD; Japan 1994.

Mahmood W. Itraconazole solution for fluconazole—refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. 386B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.

King C. Survival, death and desensitization to trimethoprim/sulphamethexazole (TMP/SMX). 388B, Tenth International Conference on AIDS/International Conference on STD. Japan 1994.